NXL Nexalin Technology, Inc. stock chart & analysis
Conviction 49HealthcareScan · Thu, Nov 19, 2026Nexalin Technology, Inc. (NXL) closed at $1.38 (-4.17%) on Nov 19, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 30, RS Rating 2, -95.9% from its 52-week high, -91.8% year to date. Sector: Healthcare · Electromedical & Electrotherapeutic Apparatus.
Why NXL moved
From the StockSetups movers recaps that covered NXL, newest first. A recap states what was known that day.
- Close+72.9%
Nexalin Technology closed up 72.9% at $7.40, with volume hitting 64.6 million shares against a 20-day average of roughly 3.25 million — nearly 20× normal turnover. NXL also appeared in this morning's premarket movers scan; see our Premarket Movers Oct 1, 2026 recap for the early setup context.
Top Stock Movers Oct 1, 2026: SSM, NXL, VEEA → - Premarket+48.6%
The most prominent recent filing on NXL is a bearish 8-K filed September 28 flagging delisting risk from Nasdaq.
Premarket Movers Oct 1, 2026: NXL, SDEV, VEEA →
Financials as of Wed, Sep 30, 2026 · quarterly.
NXL technical analysis
Trend
NXL is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 54.9% below the 50-day ($3.06) and 85.8% below the 200-day ($9.73). ADX(14) at 19 points to a weak trend — more range than direction. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 30, in oversold territory. The MACD histogram is positive. Its RS Rating of 2 puts its weighted 12-month performance ahead of about 2% of the US market.
Volume and volatility
Volume on the latest session ran 0.5× its 20-day average. It trades about $38,158 a day on average. ATR(14) is $0.2730, 19.8% of price — its typical daily range. Bollinger Bands are in a squeeze (3 sessions) — volatility is compressed. On-balance volume is trending down.
Key levels
The chart pattern's support is $1.33 and its resistance $6.76. The 52-week range is $1.31 to $33.60; price is 95.9% below the high and 5.3% above the low. The VWAP anchored at the 52-week high is $8.43, above price.
Performance
NXL returned -7.4% (1 week), -32.0% (1 month), -86.2% (3 months), -88.5% (6 months), -95.7% (1 year), -91.8% (year to date).
About Nexalin Technology, Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Electromedical & Electrotherapeutic Apparatus · Listed 2022 · 8 employees
SEC filings
EDGAR filings in NXL · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.